Line Uhrenholt

416 total citations
14 papers, 145 citations indexed

About

Line Uhrenholt is a scholar working on Rheumatology, Hematology and Infectious Diseases. According to data from OpenAlex, Line Uhrenholt has authored 14 papers receiving a total of 145 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Rheumatology, 7 papers in Hematology and 2 papers in Infectious Diseases. Recurrent topics in Line Uhrenholt's work include Rheumatoid Arthritis Research and Therapies (9 papers), Autoimmune and Inflammatory Disorders Research (7 papers) and Spondyloarthritis Studies and Treatments (5 papers). Line Uhrenholt is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (9 papers), Autoimmune and Inflammatory Disorders Research (7 papers) and Spondyloarthritis Studies and Treatments (5 papers). Line Uhrenholt collaborates with scholars based in Denmark, United Kingdom and United States. Line Uhrenholt's co-authors include Salome Kristensen, Lene Dreyer, Henrik Nielsen, René Cordtz, Christian Torp‐Pedersen, Jesper Lindhardsen, Robin Christensen, Annette Schlemmer, Ellen‐Margrethe Hauge and A. Schlemmer and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and British Journal of Clinical Pharmacology.

In The Last Decade

Line Uhrenholt

13 papers receiving 143 citations

Peers

Line Uhrenholt
Verena Schoenau Germany
Xabier Michelena Spain
Fabrizio Gozzi Italy
Monika Ronneberger Germany
Emily Kowalski United States
Jesus Loarce‐Martos Spain
Angela McArdle Ireland
M. Bézier France
Benoît Nespola France
Colline Wong United States
Verena Schoenau Germany
Line Uhrenholt
Citations per year, relative to Line Uhrenholt Line Uhrenholt (= 1×) peers Verena Schoenau

Countries citing papers authored by Line Uhrenholt

Since Specialization
Citations

This map shows the geographic impact of Line Uhrenholt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Line Uhrenholt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Line Uhrenholt more than expected).

Fields of papers citing papers by Line Uhrenholt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Line Uhrenholt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Line Uhrenholt. The network helps show where Line Uhrenholt may publish in the future.

Co-authorship network of co-authors of Line Uhrenholt

This figure shows the co-authorship network connecting the top 25 collaborators of Line Uhrenholt. A scholar is included among the top collaborators of Line Uhrenholt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Line Uhrenholt. Line Uhrenholt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Uhrenholt, Line, Lene Dreyer, Robin Christensen, et al.. (2024). Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial. Rheumatology International. 44(10). 1897–1908.
2.
Uhrenholt, Line, Robin Christensen, Lene Dreyer, et al.. (2023). Predicting successful biologics tapering in patients with inflammatory arthritis: Secondary analyses based on the BIOlogical Dose OPTimisation (BIODOPT) trial. British Journal of Clinical Pharmacology. 89(10). 3152–3164. 1 indexed citations
3.
Uhrenholt, Line, Robin Christensen, Lene Dreyer, et al.. (2023). Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a pragmatic, randomized, open-label, equivalence trial. Scandinavian Journal of Rheumatology. 52(5). 481–492. 6 indexed citations
4.
Uhrenholt, Line, et al.. (2022). Isolation in patients with inflammatory rheumatic diseases during COVID-19 pandemic compared to healthy individuals: a questionnaire survey. Rheumatology International. 42(5). 783–790. 1 indexed citations
5.
Uhrenholt, Line, Robin Christensen, Stine Linding Andersen, et al.. (2021). Tapering and Withdrawal of Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Inflammatory Arthritis:A Systematic Review and Meta-Analyses of Randomised Trials. VBN Forskningsportal (Aalborg Universitet). 1 indexed citations
6.
7.
8.
Uhrenholt, Line, Robin Christensen, Lene Dreyer, et al.. (2021). Patient-reported outcome measures in systemic lupus erythematosus by a web-based application: A randomized, crossover, agreement study. Lupus. 30(13). 2124–2134. 2 indexed citations
9.
Cordtz, René, Jesper Lindhardsen, Line Uhrenholt, et al.. (2020). Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark. Lara D. Veeken. 60(SI). SI59–SI67. 82 indexed citations
10.
11.
12.
Uhrenholt, Line, et al.. (2018). [Acute abdominal vasculitis in rheumatic diseases].. PubMed. 180(24). 1 indexed citations
13.
Uhrenholt, Line, Michael Bachmann Nielsen, & Lise Christensen. (1986). Granular cell tumor of the uvula. European Archives of Oto-Rhino-Laryngology. 243(5). 293–295. 3 indexed citations
14.
Uhrenholt, Line & Hans Stimpel. (1984). [Abscess formation in ectopic pancreatic tissue in the stomach].. PubMed. 146(12). 883–4. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Verena Schoenau Breakdown of academic impact, for papers by Xabier Michelena Breakdown of academic impact, for papers by Fabrizio Gozzi Breakdown of academic impact, for papers by Monika Ronneberger Breakdown of academic impact, for papers by Emily Kowalski Breakdown of academic impact, for papers by Jesus Loarce‐Martos Breakdown of academic impact, for papers by Angela McArdle Breakdown of academic impact, for papers by M. Bézier Breakdown of academic impact, for papers by Benoît Nespola Breakdown of academic impact, for papers by Colline Wong
Rankless by CCL
2026